Key result
Noninvasive imaging modalities and novel serum markers have the potential to measure atherosclerosis and gauge risk to guide systemic therapy in the primary prevention of coronary heart disease.
This review emphasizes the integration of novel noninvasive imaging and serum markers with conventional risk factors to optimize primary prevention strategies in cardiology.
No takes yet. Share an insight, caveat, or question.
Risk assessment guides preventive intensity; Level 4 data leaves open refinement by novel markers.
Thomas A. Pearson (2002) conducted a review in coronary heart disease. Noninvasive imaging modalities and novel serum markers have the potential to measure atherosclerosis and gauge risk to guide systemic therapy in the primary prevention of coronary heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: